MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hiv.70112

Медицинская библиотека · HIV medicine · 2025

Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States: Findings from the antiretroviral pregnancy registry.

Short William R, Willame Corinne, Nguyen Henry, Zhang Bohui, Xu Ping, Birmingham Eileen, Van Solingen-Ristea Rodica, Baugh Bryan

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

The Antiretroviral Pregnancy Registry (APR) is designed to detect major teratogenic effects of antiretroviral medications; other pregnancy outcomes are also recorded when reported. We compared available pregnancy and birth outcomes of women exposed to oral rilpivirine-containing regimens (oral-RPV cohort) versus non-rilpivirine regimens (non-RPV cohort) over the period 2011 to 2023.

METHODS

Maternal age-adjusted prevalence ratio (aPR) of pregnancy and birth outcomes was compared for prospectively reported pregnancies; aPR of birth defects was compared between first-trimester exposures and combined second/third-trimester exposures.

RESULTS

In total, 6937 pregnancies were recorded, including 4617 (oral-RPV cohort, 781 [16.9%]; non-RPV cohort, 3836 [83.1%]) from the United States. Among live births, the prevalence of birth defects was lower in the oral-RPV cohort (1.6% versus 3.8%; aPR: 0.4 [95% confidence interval (CI): 0.2-0.8]). The prevalence of birth defects in the first-trimester oral-RPV exposure versus second/third-trimester exposure did not differ (aPR: 3.4 [95% CI: 0.4-26.3]). The aPR of induced abortions (1.1 [0.6-1.9]), stillbirths (0.6 [0.2-1.6]) and premature birth (0.8 [0.7-1.1]) were similar between cohorts. Prevalences for spontaneous abortion were 5.8% (oral-RPV cohort) versus 3.2% (non-RPV cohort) below the expected background rate (15%-20%). Low birth weights were less reported in oral-RPV, while very low birth weights were similar between cohorts.

CONCLUSIONS

Review of available data from the APR does not indicate an association between adverse pregnancy or birth outcomes and oral-RPV exposure, overall or by timing of exposure. Since APR targets primarily teratogenic effects, findings for non-teratogenic effects should be interpreted with caution.

Для цитирования: Short William R, Willame Corinne, Nguyen Henry, Zhang Bohui, Xu Ping, Birmingham Eileen, Van Solingen-Ristea Rodica, Baugh Bryan. Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States: Findings from the antiretroviral pregnancy registry.. HIV medicine. 2025. DOI: 10.1111/hiv.70112.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.